Reut Fluss

Reut Fluss

Auto-generated profile, based on publicly available information

Reut Fluss

Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel. 2

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2024 in Blood Cancer Discovery
Verified
Journal Article
Closed access
MRMeir Rozenbaum
Meir Rozenbaum
RFReut Fluss
Reut Fluss
VMVictoria Marcu-Malina
Victoria Marcu-Malina
ISIfat Sarouk
Ifat Sarouk
AMAmilia Meir
Amilia Meir
EJElad Jacoby
Elad Jacoby
Somatic variants in DNA damage response genes such as ATM are widespread in hematologic malignancies. ATM protein is essential for double-strand DNA break repair. Germline ATM deficiencies underlie ataxia–telangiectasia (A–T), a disease manifested by radiosensitivity, immunodeficiency, and predisposition to lymphoid malignancies. Patients with A–T diagnosed with malignancies have poor tolerance to chemotherapy or radiation. In this study, we investigated chimeric antigen receptor (CAR) T cells using primary T cells from patients with A–T (ATM−/−), heterozygote donors (ATM+/−), and healthy donors. ATM−/− T cells proliferate and can be successfully transduced with CARs, though functional impairment of ATM−/− CAR T-cells was observed. Retroviral transduction of the CAR in ATM−/− T cells resulted in high rates of chromosomal lesions at CAR insertion sites, as confirmed by next-generation long-read sequencing. This work suggests that ATM is essential to preserve genome integrity of CAR T-cells during retroviral manufacturing, and its lack poses a risk of chromosomal translocations and potential leukemogenicity. Significance: CAR T-cells are clinically approved genetically modified cells, but the control of genome integrity remains largely uncharacterized. This study demonstrates that ATM deficiency marginally impairs CAR T-cell function and results in high rates of chromosomal aberrations after retroviral transduction, which may be of concern in patients with DNA repair deficiencies.

17 June 2026
Verified
Other
Open access
PDF file
MRMeir Rozenbaum
Meir Rozenbaum
RFReut Fluss
Reut Fluss
VMVictoria Marcu-Malina
Victoria Marcu-Malina
ISIfat Sarouk
Ifat Sarouk
AMAmilia Meir
Amilia Meir
EJElad Jacoby
Elad Jacoby
Viability of CAR-T cells from ATM+/+, ATM+/- and ATM-/- donors at the end of production


17 June 2026
Verified
Other
Open access
PDF file
MRMeir Rozenbaum
Meir Rozenbaum
RFReut Fluss
Reut Fluss
VMVictoria Marcu-Malina
Victoria Marcu-Malina
ISIfat Sarouk
Ifat Sarouk
AMAmilia Meir
Amilia Meir
EJElad Jacoby
Elad Jacoby
Illustration demonstrating structure of different type of reads aligned to the CAR vector

17 June 2026
Verified
Other
Open access
MRMeir Rozenbaum
Meir Rozenbaum
RFReut Fluss
Reut Fluss
VMVictoria Marcu-Malina
Victoria Marcu-Malina
ISIfat Sarouk
Ifat Sarouk
AMAmilia Meir
Amilia Meir
EJElad Jacoby
Elad Jacoby
Alignment details for reads found to be aligned to the CAR vector

1 July 2024
Verified
Other
Open access
MRMeir Rozenbaum
Meir Rozenbaum
RFReut Fluss
Reut Fluss
VMVictoria Marcu-Malina
Victoria Marcu-Malina
ISIfat Sarouk
Ifat Sarouk
AMAmilia Meir
Amilia Meir
EJElad Jacoby
Elad Jacoby
Data from Genotoxicity Associated with Retroviral CAR Transduction of ATM-Deficient T Cells